Recent developments center on the Trump administration’s December 2025 executive order directing expedited rescheduling of marijuana from Schedule I to Schedule III, followed by the April 2026 final order that immediately moved FDA-approved and state-licensed medical products to Schedule III while launching a new administrative hearing process. That hearing, which began June 29 and concluded by mid-July 2026, gathered evidence on broader reclassification but has not yet produced a final rulemaking decision. Trader consensus reflected in current market prices assigns roughly 25 percent probability to full rescheduling occurring in 2026, consistent with the procedural steps still required before any final DEA or Attorney General action can take effect. Key variables ahead include the timing of any post-hearing recommendation, potential legal challenges, and agency resource allocation under the Controlled Substances Act.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update$791,969 Vol.
Mar 31, 2026
September 30
14%
December 31
28%
$791,969 Vol.
September 30
$0 Vol.
14%
December 31
$182,399 Vol.
28%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent developments center on the Trump administration’s December 2025 executive order directing expedited rescheduling of marijuana from Schedule I to Schedule III, followed by the April 2026 final order that immediately moved FDA-approved and state-licensed medical products to Schedule III while launching a new administrative hearing process. That hearing, which began June 29 and concluded by mid-July 2026, gathered evidence on broader reclassification but has not yet produced a final rulemaking decision. Trader consensus reflected in current market prices assigns roughly 25 percent probability to full rescheduling occurring in 2026, consistent with the procedural steps still required before any final DEA or Attorney General action can take effect. Key variables ahead include the timing of any post-hearing recommendation, potential legal challenges, and agency resource allocation under the Controlled Substances Act.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Binuksan ang Market: Feb 7, 2026, 5:04 PM ET
Volume
$791,969Petsa ng Pagtatapos
Mar 31, 2026Binuksan ang Market
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent developments center on the Trump administration’s December 2025 executive order directing expedited rescheduling of marijuana from Schedule I to Schedule III, followed by the April 2026 final order that immediately moved FDA-approved and state-licensed medical products to Schedule III while launching a new administrative hearing process. That hearing, which began June 29 and concluded by mid-July 2026, gathered evidence on broader reclassification but has not yet produced a final rulemaking decision. Trader consensus reflected in current market prices assigns roughly 25 percent probability to full rescheduling occurring in 2026, consistent with the procedural steps still required before any final DEA or Attorney General action can take effect. Key variables ahead include the timing of any post-hearing recommendation, potential legal challenges, and agency resource allocation under the Controlled Substances Act.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$791,969Petsa ng Pagtatapos
Mar 31, 2026Binuksan ang Market
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...Recent developments center on the Trump administration’s December 2025 executive order directing expedited rescheduling of marijuana from Schedule I to Schedule III, followed by the April 2026 final order that immediately moved FDA-approved and state-licensed medical products to Schedule III while launching a new administrative hearing process. That hearing, which began June 29 and concluded by mid-July 2026, gathered evidence on broader reclassification but has not yet produced a final rulemaking decision. Trader consensus reflected in current market prices assigns roughly 25 percent probability to full rescheduling occurring in 2026, consistent with the procedural steps still required before any final DEA or Attorney General action can take effect. Key variables ahead include the timing of any post-hearing recommendation, potential legal challenges, and agency resource allocation under the Controlled Substances Act.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update
Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong